JP7034151B2 - プロペプチドntsr3に由来するペプチド、及びうつ病の治療におけるその使用 - Google Patents
プロペプチドntsr3に由来するペプチド、及びうつ病の治療におけるその使用 Download PDFInfo
- Publication number
- JP7034151B2 JP7034151B2 JP2019518949A JP2019518949A JP7034151B2 JP 7034151 B2 JP7034151 B2 JP 7034151B2 JP 2019518949 A JP2019518949 A JP 2019518949A JP 2019518949 A JP2019518949 A JP 2019518949A JP 7034151 B2 JP7034151 B2 JP 7034151B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- spadin
- depression
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
Description
したがって、ADを得るのに必要な3~6週間の時間をモノアミンのシナプスレベルの増加と相関させることは困難であり、これは製品の最初の投与と同時に起こる。半世紀近く、うつ病の病因とその治療法に関する仮説の数は増え続けている。
- 宿主細胞を本発明による核酸でトランスフェクトすること、または本発明のベクターで宿主細胞を形質転換する工程;
- 本発明によるペプチドの発現を可能にする条件下で前記宿主細胞を培養する工程;及び
- 前記ペプチドを回収する工程。
スパジン類似体およびスパジンの効果を測定するすべての実験は、TREK-1チャネル、hTREK-1/HEK293で安定的にトランスフェクトされたβTC3またはLNCaPまたはHEK293細胞に対して行われた。hTREK-1/HEK293細胞株は研究室で調製された[21]。これらの細胞はまたレポーター遺伝子:それらの可視化を可能にするE-グリーン蛍光タンパク質(EGFP)を発現する。
強制泳動試験(FST)
物質の抗うつ活性を決定するために古典的行動試験が開発された(Nestier E.J. et al、2002、Cryan J. and Holmes A.、2005)[22~23]。本発明のスパジン類似体の効果を、本発明のスパジン類似体が溶解されている食塩水の効果およびスパジンの効果と比較した。使用したマウス系統は、C57BI/6J系統であった。
学習した甘受または学習した無力感は、動物に甘受状態を誘導するための電気ショックの反復投与に基づくモデルである。確かに、避けられない電気ショックを受けた動物はそれらを受けることを甘受し、逃げようとしないことが示されている(SeligmanおよびBeagley、ラットJ Comp Physiol Psychol 88、534-541、1975)[24]。
免疫組織化学による神経発生の研究
BrdU(5-ブロモ-2’-デオキシウリジン)は、チミジンに類似の合成ヌクレオシドである。分裂中の細胞のS期(間期中の染色体複製)中のDNA複製中に取り込まれる。 BrdUの注射は、免疫学的標識によって分析されるべき組織の分割における細胞を視覚化することを可能にする。本研究では、マウスの海馬神経発生を、スパジンまたは異なる類似体での治療後に評価した。
妊娠した雌C57Bl/6Jマウス(20~25g、Janvier Labs、St Berthevin、フランス)を、30%酸素および70%亜酸化窒素と混合した2%イソフルランの吸入によって麻酔し、次いで屠殺した。胚(E14)を取り出し、大脳皮質を1%グルコースを含有するPBS中で解剖した。ニューロンは、Brewer and Torricelli、2007[26]に記載されているように、大脳皮質から機械的解離によって調製した。解離したニューロンをポリ-L-リジン処理プレートに分配し、37℃で2%B27(Invitrogen、Fisher Scientific、Illkirch、フランス)および50μg / mlゲンタマイシン(Sigma、フランス)を含有する神経基礎培地中で最大10日間培養した。 5%CO2下での温度。
Claims (10)
- 22位のグリシンがアラニンで置換された配列番号3の配列に対応する配列番号7の配列(AVSWGLR)からなるペプチドG/A-PE(22~28)、及びビオチン化された配列番号7の配列からなるビオチン化ペプチドG/A-PE(22~28)から選択されるニューロテンシン受容体3(NTSR3)のプロペプチド(PE)由来のペプチド。
- 22位のグリシンがアラニンで置換された配列番号3の配列に対応する配列番号7の配列(AVSWGLR)からなるペプチドG/A-PE(22~28)をコードする核酸。
- 請求項2に記載の核酸を含むベクター。
- 請求項1に記載のペプチドおよび/または請求項2に記載の核酸および/または請求項3に記載のベクターを含む宿主細胞。
- - 請求項2に記載の核酸で宿主細胞をトランスフェクトする工程、または請求項3に記載のベクターで宿主細胞を形質転換する工程;
- 前記ペプチドの発現を可能にする条件下で前記宿主細胞を培養する工程;及び
- 前記ペプチドを回収する工程
を含む、請求項1に記載のペプチドの製造方法。 - 医薬として使用するための請求項1に記載のペプチド。
- 前記医薬が抗うつ薬である、請求項6に記載の使用のためのペプチド。
- うつ病の治療に使用するための、請求項1に記載のペプチド。
- 糖尿病または癌の治療に使用するための、請求項1に記載のペプチド。
- てんかんまたは卒中に対する神経保護に使用するための請求項1に記載のペプチド。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1659781A FR3057267A1 (fr) | 2016-10-11 | 2016-10-11 | Procede de diagnostic/determination de l'efficacite de traitement de la depression |
FR1659781 | 2016-10-11 | ||
FR1752162 | 2017-03-16 | ||
FR1752162A FR3057268B1 (fr) | 2016-10-11 | 2017-03-16 | Procede de diagnostic/determination de l'efficacite de traitement de la depression |
FR1754127A FR3057266B1 (fr) | 2016-10-11 | 2017-05-11 | Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression |
FR1754127 | 2017-05-11 | ||
PCT/FR2017/052788 WO2018069641A1 (fr) | 2016-10-11 | 2017-10-11 | Peptides dérivés du propeptide ntsr3 et leur utilisation dans le traitement de la dépression |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020502995A JP2020502995A (ja) | 2020-01-30 |
JP7034151B2 true JP7034151B2 (ja) | 2022-03-11 |
Family
ID=59297081
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019518384A Pending JP2019534259A (ja) | 2016-10-11 | 2017-10-11 | うつ病治療の有効性を診断/決定するための方法 |
JP2019518949A Active JP7034151B2 (ja) | 2016-10-11 | 2017-10-11 | プロペプチドntsr3に由来するペプチド、及びうつ病の治療におけるその使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019518384A Pending JP2019534259A (ja) | 2016-10-11 | 2017-10-11 | うつ病治療の有効性を診断/決定するための方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20200190172A1 (ja) |
EP (2) | EP3526244B1 (ja) |
JP (2) | JP2019534259A (ja) |
CA (2) | CA3039273A1 (ja) |
DK (1) | DK3526244T3 (ja) |
ES (1) | ES2965080T3 (ja) |
FI (1) | FI3526244T3 (ja) |
FR (3) | FR3057267A1 (ja) |
HR (1) | HRP20231567T1 (ja) |
PT (1) | PT3526244T (ja) |
WO (2) | WO2018069641A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114544821B (zh) * | 2020-11-24 | 2023-10-24 | 重庆医科大学 | 检测血浆中磷脂酰乙醇胺(36:4)的试剂在制备抑郁症检测试剂盒中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011505864A (ja) | 2007-12-21 | 2011-03-03 | サントル ナショナル ドゥ ラ ルシェルシュ スィヤンティフィック(セーエヌエルエス) | ニューロテンシン受容体3に由来するペプチドおよび精神疾患の治療におけるその使用 |
WO2015110915A2 (en) | 2014-01-27 | 2015-07-30 | Medincell | Retro-inverso analogs of spadin display increased antidepressant effects |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE545429T1 (de) | 2002-12-20 | 2012-03-15 | Lundbeck & Co As H | Modulation der neurotrophinaktivität;screeningsverfahren |
US20120322060A1 (en) * | 2011-04-13 | 2012-12-20 | Centre National De Le Recherche Scientifique - Cnrs - | Diagnosis and monitoring treatment of psychiatric diseases with spadin and related methods |
JP2017508144A (ja) * | 2014-02-12 | 2017-03-23 | ハー・ルンドベック・アクチエゼルスカベット | 感情/気分障害のバイオマーカーとしてのソルチリンの使用 |
-
2016
- 2016-10-11 FR FR1659781A patent/FR3057267A1/fr active Pending
-
2017
- 2017-03-16 FR FR1752162A patent/FR3057268B1/fr active Active
- 2017-10-11 EP EP17794365.1A patent/EP3526244B1/fr active Active
- 2017-10-11 EP EP17794364.4A patent/EP3526243A2/fr active Pending
- 2017-10-11 DK DK17794365.1T patent/DK3526244T3/da active
- 2017-10-11 CA CA3039273A patent/CA3039273A1/fr active Pending
- 2017-10-11 ES ES17794365T patent/ES2965080T3/es active Active
- 2017-10-11 PT PT177943651T patent/PT3526244T/pt unknown
- 2017-10-11 WO PCT/FR2017/052788 patent/WO2018069641A1/fr unknown
- 2017-10-11 FI FIEP17794365.1T patent/FI3526244T3/en active
- 2017-10-11 JP JP2019518384A patent/JP2019534259A/ja active Pending
- 2017-10-11 US US16/341,158 patent/US20200190172A1/en not_active Abandoned
- 2017-10-11 CA CA3040054A patent/CA3040054A1/fr active Pending
- 2017-10-11 HR HRP20231567TT patent/HRP20231567T1/hr unknown
- 2017-10-11 WO PCT/FR2017/052787 patent/WO2018069640A2/fr unknown
- 2017-10-11 JP JP2019518949A patent/JP7034151B2/ja active Active
- 2017-10-11 US US16/340,832 patent/US11220527B2/en active Active
-
2018
- 2018-07-10 FR FR1856341A patent/FR3068697A1/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011505864A (ja) | 2007-12-21 | 2011-03-03 | サントル ナショナル ドゥ ラ ルシェルシュ スィヤンティフィック(セーエヌエルエス) | ニューロテンシン受容体3に由来するペプチドおよび精神疾患の治療におけるその使用 |
WO2015110915A2 (en) | 2014-01-27 | 2015-07-30 | Medincell | Retro-inverso analogs of spadin display increased antidepressant effects |
Also Published As
Publication number | Publication date |
---|---|
WO2018069640A3 (fr) | 2018-06-07 |
WO2018069641A1 (fr) | 2018-04-19 |
ES2965080T3 (es) | 2024-04-11 |
US20200190172A1 (en) | 2020-06-18 |
US11220527B2 (en) | 2022-01-11 |
FR3057267A1 (fr) | 2018-04-13 |
CA3040054A1 (fr) | 2018-04-19 |
EP3526244B1 (fr) | 2023-09-06 |
HRP20231567T1 (hr) | 2024-03-15 |
EP3526244A1 (fr) | 2019-08-21 |
JP2019534259A (ja) | 2019-11-28 |
FR3068697A1 (fr) | 2019-01-11 |
FI3526244T3 (en) | 2023-12-11 |
FR3057268A1 (fr) | 2018-04-13 |
US20190270771A1 (en) | 2019-09-05 |
WO2018069640A2 (fr) | 2018-04-19 |
EP3526243A2 (fr) | 2019-08-21 |
PT3526244T (pt) | 2023-12-11 |
DK3526244T3 (da) | 2023-12-11 |
CA3039273A1 (fr) | 2018-04-19 |
JP2020502995A (ja) | 2020-01-30 |
FR3057268B1 (fr) | 2021-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Müller et al. | Astrocyte-derived CNTF switches mature RGCs to a regenerative state following inflammatory stimulation | |
Marschallinger et al. | Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug | |
JP6163104B2 (ja) | ヒト・トロホブラスト幹細胞からの神経幹細胞の生成 | |
Garofalo et al. | Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice | |
Shang et al. | Intracerebral GM-CSF contributes to transendothelial monocyte migration in APP/PS1 Alzheimer’s disease mice | |
Katakowski et al. | Stroke-induced subventricular zone proliferation is promoted by tumor necrosis factor-α-converting enzyme protease activity | |
Ohta et al. | Pituitary adenylate cyclase‐activating polypeptide regulates forebrain neural stem cells and neurogenesis in vitro and in vivo | |
Yang et al. | Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1β/CXCR7–AMPK/p38-MAPK/IL-6 axis | |
US20170202910A1 (en) | Differentiation marker and differentiation control of eye cell | |
JP7034151B2 (ja) | プロペプチドntsr3に由来するペプチド、及びうつ病の治療におけるその使用 | |
Yoshimura et al. | Roles of 5-HT1A receptor in the expression of AMPA receptor and BDNF in developing mouse cortical neurons | |
Liu et al. | CCL28 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus | |
Namiki et al. | Chitinase-like protein 3: A novel niche factor for mouse neural stem cells | |
Glöckler et al. | Comparison and evaluation of MVC measurements from selected reference tasks | |
JP2004123679A (ja) | 好酸球カチオン性タンパク質を含有する組成物 | |
Gómez Oliva | Cell replacement strategies in the central nervous system in two mouse models of neuronal damage: potential therapeutic targets and promising drugs | |
WO2019188950A1 (ja) | 医薬組成物 | |
FR3057266A1 (fr) | Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression | |
Guzman | Aging, Oxidative Stress, and Schwann Cell Regulation: Implications for Neuromuscular Health | |
Neuro | Society for Research in Neurosciences | |
Sze et al. | Structure-function study of ubiquitin c-terminal hydrolase L1 (UCH-L1) by NMR spectroscopy-insights into UCH-L1 mutation's association with the risk of Parkinson's disease | |
CN116407634A (zh) | 增加Slack蛋白C端含量的物质的应用 | |
Yang et al. | Protective effects of lycium barbarum polysaccharides on cerebral edema and blood-brain barrier disruption after ischemic stroke | |
Lam et al. | Regulatory role of proheparanase with peri-synaptic heparan sulfate proteoglycan and AMPA-type glutamate receptor in synaptic plasticity | |
Oscar-Berman et al. | Welcome to the Twentieth Annual Henry I. Russek Student Achievement Day! |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200911 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210621 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220131 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220301 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7034151 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |